Antiplatelet therapy with oral P2Y12-receptor inhibitors (clopidogrel, prasugrel, and ticagrelor) is widely used in patients with acute coronary syndrome and those undergoing percutaneous coronary intervention. However, patients often need to switch between these drugs for a variety of clinical reasons. In this Review, Rollini et al. summarize the practical considerations when switching therapies, including discussion of the new intravenous P2Y12-receptor inhibitor cangrelor.
- Fabiana Rollini
- Francesco Franchi
- Dominick J. Angiolillo
